Nigeria's health sector reforms, initiated under President Bola Ahmed Tinubu, are generating economic benefits that extend far beyond improved healthcare outcomes. According to Okey Akpa, PhD, Managing Director of SKG Pharma and former Chairman of the Pharmaceutical Group of Manufacturers' Association of Nigeria, the reforms are attracting investment, expanding domestic manufacturing, strengthening human capital, and building scientific and institutional capability, all of which contribute to the foundations of long-term economic growth.
Reforms Creating a Coherent Health System
The reforms began on 12 December 2023 with the launch of the Nigeria Health Sector Renewal Investment Initiative (NHSRII) under the Renewed Hope Agenda. The initiative, implemented through the Sector-Wide Approach (SWAp), replaced fragmented interventions with a common plan, shared priorities, and a stronger accountability framework. Under the leadership of Coordinating Minister of Health and Social Welfare, Professor Muhammad Ali Pate, the framework has been pursued with sustained discipline.
Since 2023, more than six million Nigerians have entered organised health insurance, expanding the market for healthcare services. Over 4,100 primary healthcare centres are under revitalisation, with more than 3,100 already completed. Reforms to the Basic Healthcare Provision Fund are making frontline financing more reliable, and investments in the health workforce and specialist care are expanding the system's capacity.
Investment Flows Into Health Sector
The Presidential Initiative to Unlock the Healthcare Value Chain (PVAC) has become a key instrument for translating confidence into investment. More than ninety investment projects, representing a pipeline valued at over US$5 billion, are under development across pharmaceuticals, vaccines, diagnostics, medical oxygen, and medical devices. Afreximbank's US$1 billion financing platform, alongside additional financing from the European Investment Bank and the Bank of Industry, is widening access to long-term capital.
Companies that once viewed Nigeria primarily as a destination for imported products are increasingly investing in local production, assembly, and technology partnerships. Established manufacturers are expanding operations in response to a clearer long-term market direction.
Domestic Manufacturing Expansion
The reforms aim to build an integrated healthcare manufacturing ecosystem capable of serving a growing domestic market while positioning Nigerian firms to compete across regional and global value chains. The Presidential Executive Order on local manufacturing, market-shaping interventions, pooled procurement through Medipool, and strategic partnerships are all directed towards this objective.
Investment is expanding pharmaceutical manufacturing, oxygen production, diagnostics, rapid diagnostic tests, treated bed nets, and medical technologies. Every additional stage of production retained within Nigeria strengthens domestic value chains, supports local enterprise, creates skilled employment, and retains more economic value within the national economy.
Human Capital Development
More than 78,000 frontline health workers have already been retrained, with a target of 120,000. Recruitment has expanded across federal tertiary health institutions, while the National Health Fellowship is preparing a new generation of public sector leaders from all 774 local government areas.
The reforms recognise international migration as a structural feature of the labour market and focus on expanding the pipeline of skilled professionals, improving working conditions, strengthening career pathways, and promoting ethical international recruitment. A larger and better-trained workforce strengthens productivity, supports scientific research, reinforces domestic manufacturing, and expands technical capabilities.
Building Scientific and Institutional Capability
Clinical trial capacity is expanding, positioning Nigeria to play a larger role in the development and evaluation of new medicines, vaccines, and medical technologies. Investments in genomics are strengthening disease surveillance and broadening scientific capabilities. Regulatory reforms are reinforcing confidence in the quality, safety, and integrity of Nigerian health products.
The reforms are also strengthening collaboration among universities, research institutions, industry, and government, shortening the distance between scientific discovery and commercial application.
Conclusion
Healthcare reforms will always be judged first by their impact on people's lives, but the experience of the past three years suggests that reforms on this scale can achieve more than better health outcomes. By creating a more coherent health system, attracting investment, expanding domestic manufacturing, strengthening human capital, and building scientific and institutional capability, they are also contributing to the foundations of long-term economic growth. This is an important lesson for a country pursuing the ambition of building a one-trillion-dollar economy. Conceived to improve the health of Nigerians, the reforms are also beginning to reshape the productive capacity of the economy itself.
